MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

35.65 0.88

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

34.21

Max

35.65

Schlüsselkennzahlen
By Trading Economics
Einkommen	-22M -102M
Angestellte	258
EBITDA	-30M -109M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+48.36% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	141M 5.7B
Vorheriger Eröffnungskurs	34.77
Vorheriger Schlusskurs	35.65

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Apr. 2026, 17:26 UTC

Wichtige Nachrichtenereignisse

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7. Apr. 2026, 23:55 UTC

Market Talk

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7. Apr. 2026, 23:47 UTC

Market Talk

Wichtige Nachrichtenereignisse

Market Talk Roundup: Latest on U.S. Politics

7. Apr. 2026, 23:47 UTC

Market Talk

Wichtige Nachrichtenereignisse

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7. Apr. 2026, 23:44 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7. Apr. 2026, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

7. Apr. 2026, 23:42 UTC

Market Talk

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7. Apr. 2026, 23:37 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7. Apr. 2026, 23:15 UTC

Market Talk

Wichtige Nachrichtenereignisse

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7. Apr. 2026, 23:04 UTC

Wichtige Nachrichtenereignisse

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7. Apr. 2026, 23:04 UTC

Wichtige Nachrichtenereignisse

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7. Apr. 2026, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Apr. 2026, 23:03 UTC

Market Talk

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7. Apr. 2026, 23:01 UTC

Wichtige Nachrichtenereignisse

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7. Apr. 2026, 22:58 UTC

Wichtige Nachrichtenereignisse

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7. Apr. 2026, 21:56 UTC

Akquisitionen, Fusionen, Übernahmen

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

7. Apr. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. Apr. 2026, 19:45 UTC

Market Talk

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7. Apr. 2026, 19:17 UTC

Wichtige Nachrichtenereignisse

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7. Apr. 2026, 19:16 UTC

Market Talk

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7. Apr. 2026, 19:07 UTC

Market Talk

Global Energy Roundup: Market Talk

7. Apr. 2026, 19:07 UTC

Market Talk

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7. Apr. 2026, 18:41 UTC

Akquisitionen, Fusionen, Übernahmen

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7. Apr. 2026, 18:40 UTC

Akquisitionen, Fusionen, Übernahmen

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7. Apr. 2026, 18:39 UTC

Akquisitionen, Fusionen, Übernahmen

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7. Apr. 2026, 18:24 UTC

Wichtige Nachrichtenereignisse

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. Apr. 2026, 17:08 UTC

Market Talk

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7. Apr. 2026, 16:21 UTC

Wichtige Nachrichtenereignisse

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. Apr. 2026, 16:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

48.36% Vorteil

12-Monats-Prognose

Durchschnitt 52.55 USD 48.36%

Hoch 64 USD

Tief 35 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.